Protein-Level Analysis of Differential Response to Chemotherapy in Triple-Negative Breast Cancer Identifies CYP1B1 as a Biomarker for Chemotherapy Resistance
This retrospective analysis of pretreatment TNBC core biopsies found that elevation of CYP1B1, a drug-metabolizing enzyme in tumor cells, was associated with resistance to NAC in patients with TNBC treated initially with doxorubicin. If confirmed, this pattern of chemotherapy resistance could guide future clinical trials.
Authors
- Paul D. Gershon (ORCID: https://orcid.org/0000-0002-4904-9193)
- F. Scott Heinemann
Institutions
- Hoag Memorial Hospital Presbyterian (US)
- University of California, Irvine (US)
- Irvine University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0034
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health